Ono Achieves Target Reduction of Sales Ratio of Long-Listed Drugs to Mid-50% Level: President Sagara

Gyo Sagara, President, Representative Director and CEO, Ono Pharmaceutical At an earnings briefing held on November 5 for the consolidated settlement of accounts for April-September 2012, Gyo Sagara, president, representative director and CEO of Ono Pharmaceutical, revealed that the company...read more